Author:
Chiu Chong-Chi,Hsieh Mao-Chih,Wang Guan-Ling,Shi Hon-Yi
Reference44 articles.
1. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial;F Qu�net;Lancet Oncol,2021
2. Survival differences between the USA and an urban population from China for all cancer types and 20 individual cancers: a population-based study;R Fu;Lancet Reg Health West Pac,2023
3. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial;S L Aronson;Lancet Oncol,2023
4. Quality of life in a phase 2 trial of short-course hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking surgery for high tumor burden ovarian cancer;Rjc Lustosa;Rev Col Bras Cir,2020
5. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study;L B Wenzel;J Clin Oncol,2007